GLP-1 receptor agonists, particularly new generation agents such as semaglutide and tirzepatide, may significantly reduce the risk for arthroplasty in patients with knee osteoarthritis, data show.“In musculoskeletal medicine, we are at an early and exciting stage regarding the use of GLP-1s,” Jay V. Karri, MD, MPH, assistant professor of pain medicine at the University of

GLP-1 receptor agonists, particularly new generation agents such as semaglutide and tirzepatide, may significantly reduce the risk for arthroplasty in patients with knee…

CHICAGO — In this video, Elizabeth S. McDonald, MD, discusses a retrospective, time-dependent cohort study evaluating GLP-1 receptor agonist use and breast cancer risk among women…